10-QHealthcare

Bristol-myers Squibb Company

BMY · Period ending 2026-09-30 · Filed 2026-10-29 · Updated

In short

Bristol-myers Squibb Company (BMY) has operating cash flow down 6.8% to $14.2B year on year. Its net margin is 14.6%, and it trades at 14.2× trailing earnings. Fisclear flags 1 medium-severity risk and no high-severity ones. How we calculate this

Valuation

Healthcare
Live · Yahoo Finance

Price

$58.80

Market Cap

$120.2B

P/E (TTM)

13.0x

Price ÷ earnings per share

P/B

5.1x

Price ÷ book value

P/S (TTM)

2.4x

Price ÷ revenue per share

Beta

0.19

Low volatility vs market

PEG Ratio

16.1x

P/E ÷ earnings growth rate

52-Week Range

$47.58$58.80 now$68.64

Decision Context

Market appears to be pricing in less growth than this company's historical average, suggesting potential upside if the trajectory continues. Quality and efficiency scores support the business case.

Based on filing period ending Sept 2026

FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.

BMY vs

Macro Context

Fed Funds Rate

3.88%

Accommodative

10-Year Treasury

5.13%

2026-10-01

Unemployment

4.2%

Near full employment

CPI Index

336.3

2026-09-01

M2 Money Supply

$23.4T

2026-09-01

The Federal Funds rate stands at 3.88% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 5.13%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 104.0; M2 money supply is $23.4T; CPI index stands at 336.3.

SWOT Analysis — BMY

Inflationary Boom
Macro lens (Inflationary Boom): Rising costs and tighter margins amplify financial risks in this regime.
✦

Strengths

  • Net Income: $7.1B (+178.8% YoY) — Profit grew 179% — the company kept more of each dollar earned.

  • EPS (Diluted): $3.46 (+178.5% YoY) — Earnings per share rose 178% — each share earned more.

◈

Weaknesses

  • Operating Cash Flow: $14.2B (-6.8% YoY) — Operating cash flow fell 7% but remained positive.

  • Total Assets: $90.0B (-2.8% YoY) — Total assets shrank 3% — the balance sheet contracted.

  • Revenue: $48.2B (-0.2% YoY) — Revenue fell 0% — the company generated less from its core operations.

◎

Opportunities

No clear opportunities identified at this time.

⚠

Threats

  • Total liabilities represent 79% of total assets — elevated leverage that amplifies both gains and losses.

Year-over-Year Changes

Net Income

$7.1B

was -$8.9B

+178.8%

Profit grew 179% — the company kept more of each dollar earned.

EPS (Diluted)

$3.46

was $-4.41

+178.5%

Earnings per share rose 178% — each share earned more.

Operating Cash Flow

$14.2B

was $15.2B

−6.8%

Operating cash flow fell 7% but remained positive.

Total Assets

$90.0B

was $92.6B

−2.8%

Total assets shrank 3% — the balance sheet contracted.

Revenue

$48.2B

was $48.3B

−0.2%

Revenue fell 0% — the company generated less from its core operations.

Risk Flags

0 high · 1 medium · 0 low
  • ◈ Medium

    Total liabilities represent 79% of total assets — elevated leverage that amplifies both gains and losses.

Technical Signals

Daily closes · 1-year data

Bristol-myers Squibb Company: common questions

Is Bristol-myers Squibb Company profitable?

Yes. Bristol-myers Squibb Company made a net profit of $7.1B in its latest fiscal year (fiscal 2025), a net margin of 14.6%.

What is Bristol-myers Squibb Company's P/E ratio?

Bristol-myers Squibb Company trades at 13.0× its trailing twelve-month earnings. In other words, the share price is about 13 times the profit per share the company earned over the past year.

Does Bristol-myers Squibb Company pay a dividend?

Yes. Bristol-myers Squibb Company's forward dividend yield is 4.29%, the expected annual dividend as a share of the current share price.

What are the main risks for Bristol-myers Squibb Company?

Fisclear's checks flag 1 medium- or high-severity risk. The most serious: Total liabilities represent 79% of total assets — elevated leverage that amplifies both gains and losses.

Answers are generated from the figures in this report (updated 5 Nov 2026). Information, not investment advice.

Latest News

via Finnhub

Filing History — BMY

Get the weekly digest

5 company reports + macro context every week, free. No spam.

  • Unlimited goal simulations
  • 5 free company report summaries per day
  • Weekly financial insights newsletter

External Links

Trade BMY

Links open broker research pages. Not an endorsement or recommendation.

Research Bristol-myers Squibb Company

Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.